(Q43817850)

27 November 2017

title

Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system (English)

1 reference

27 November 2017

author

Kamyar Kalantar-Zadeh

4

1 reference

27 November 2017

John J Sim

1

1 reference

27 November 2017

Simran K Bhandari

2

1 reference

27 November 2017

Jiaxiao Shi

3

1 reference

27 November 2017

Scott A Rasgon

5

1 reference

27 November 2017

Jean E Sealey

6

1 reference

27 November 2017

John H Laragh

7

1 reference

27 November 2017

publication date

8 December 2011

1 reference

Journal of Clinical Hypertension

27 November 2017

published in

1 reference

27 November 2017

volume

25

1 reference

27 November 2017

issue

3

1 reference

27 November 2017

page(s)

379-388

1 reference

US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Differential Control of Systolic and Diastolic Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Resistant hypertension: an overview of evaluation and treatment

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Treatment of hypertension: a failing report card

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Low-renin status in therapy-resistant hypertension: a clue to efficient treatment

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Resistant hypertension revisited: a comparison of two university-based cohorts.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Individual responses to converting enzyme inhibitors and calcium antagonists

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Plasma Renin Activity Predicts Blood Pressure Responses to -Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Optimisation of antihypertensive treatment by crossover rotation of four major classes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Pressor responses to antihypertensive drug types

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Renin test-guided drug treatment of hypertension: the need for clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

25-hydroxyvitamin D levels and hypertension rates

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Combination therapy in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Hypertension treatment in a medicare population: adherence and systolic blood pressure control

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Plasma renin activity for predicting antihypertensive drug efficacy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.216

7 January 2021

Identifiers

DOI

10.1038/AJH.2011.216

1 reference

27 November 2017

1 reference